Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + BCG (OncoTICE)
- Development stage
- Approved
- Lead developer
- Clinigen
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intralesional
01
Overview
This combination immunotherapy consists of intralesional injections of aldesleukin (recombinant Interleukin-2) and Bacillus Calmette-Guerin (BCG), specifically the OncoTICE strain. Aldesleukin is a cytokine that promotes the proliferation and activation of T cells and natural killer (NK) cells, enhancing the body's adaptive immune response. BCG is a live-attenuated strain of *Mycobacterium bovis* that acts as a potent biological response modifier; when injected intralesionally, it induces a localized inflammatory response and recruits immune effector cells to the tumor microenvironment. This specific combination is being investigated by Dr. Carman Giacomantonio for the treatment of cutaneous metastatic melanoma, with the goal of achieving synergistic immune stimulation to induce regression of both injected and potentially non-injected (abscopal) lesions.
- Brand names
- OncoTICEProleukin
- Other names
- IL-2 + BCGInterleukin-2 + Bacillus Calmette-GuerinIL-2 + OncoTICECombination therapy Interleukin-2 and Bacillus Calmette Guerin
02
Targets
IL2RB (IL-2 receptor beta chain)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on aldesleukin + BCG (OncoTICE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + BCG (OncoTICE).